Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes

Trial Profile

Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs T-lymphocyte cell therapy (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Breast cancer; Liver cancer; Meningioma; Non-small cell lung cancer; Solid tumours; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2017 Planned primary completion date changed from 3 Jul 2017 to 5 Jul 2027.
    • 10 Jun 2017 Biomarkers information updated
    • 05 Oct 2016 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top